Improving the treatment of bone metastasis in breast cancer
Despite advances and improvements in outcomes following breast cancer, a significant proportion will still develop metastatic disease with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease but most patients with bone involvement also have metastases in other organs. Thus, a bone-targeted treatment alone is unlikely to be relevant to the majority of patients. Combination strategies with established systemic breast cancer treatments are needed. This will be the first study to assess radium with chemotherapy in advanced breast cancer.
Prof Janet Brown from Sheffield ECMC is leading the multi-site phase IB/IIA study CARBON, to evaluate the safety and toxicity of the combination of Radium-223 and capecitabine in metastatic breast cancer patients with bone metastases.
The IB phase was completed in April 2017 and Phase IIA has commenced recruitment.
The trial is recruiting breast cancer patients with bone metastases who have received up to two lines of chemotherapy in the metastatic setting.
The NIHR portfolio badged, Yorkshire Cancer Research Centre for Early Phase Clinical Trials Collaborative study, funded by a grant from Bayer and sponsored by Sheffield Teaching Hospitals NHS Foundation Trust is open in 4 centres with 2 more in set-up.